PG11: COSTS AND PRACTICE PATTERNS ASSOCIATED WITH TREATING GASTROESOPHAGEAL REFLUX DISEASE (GERD) IN A MANAGED CARE POPULATION  by Nichol, MB et al.
200 Abstracts
ECONOMIC AND OUTCOMES ISSUES OF 
GASTROINTESTINAL DISORDERS
PGI1
COSTS AND PRACTICE PATTERNS 
ASSOCIATED WITH TREATING 
GASTROESOPHAGEAL REFLUX DISEASE 
(GERD) IN A MANAGED CARE POPULATION
Nichol MB1, Harada ASM1, Jones J1, Venturini F1, Johnson JN2, 
O’Connor RD3, Gilderman A4
1University of Southern California, Los Angeles, CA, USA; 
2Bay Shores Medical Group, Torrance, CA, USA; 3Sharp Rees-
Stealy Medical Group, San Diego, CA, USA; 4Prescription 
Solutions, Costa Mesa, CA, USA
OBJECTIVES: To document the costs, practice patterns,
patient satisfaction, and quality of life associated with
treating GERD in a managed care population. 
METHODS: This intent-to-treat study employed data
from two medical groups associated with a federally
qualified HMO in California. Patients with encounters
for IDC-9 codes: 530.00 to 530.99 (esophagus), 535.00
to 535.99 (gastritis) and 553.3 (diaphragmatic hernia)
were included. In this study 349 patients identified as be-
ginning a new GI treatment episode between 03/01/97
and 08/31/97 were sent a survey containing the MOS SF-
12 instrument and ABIM patient satisfaction survey
(score range 0–50) shortly after beginning their episode.
Patients were resurveyed 8 weeks later.
RESULTS: Surveyed patients ranged in age from 24–95
years and 58% were female. Cimetidine (59%  123/
207) was the most common H2-receptor antagonist
(H2RA) monotherapy prescribed followed by Ranitidine
(29%  60/207). Omeprazole (99%  105/106) was the
most commonly prescribed proton-pump inhibitor (PPI)
monotherapy. Treatment episode lengths, time since previ-
ous episode, and time until subsequent episode were not
significantly different for those initiating treatment on
H2RA versus PPI monotherapy. No significant changes in
baseline versus follow-up SF-12 (baseline mean PCS 
43.7, MCS  49.8) and ABIM patient satisfaction (base-
line median  44) were observed (n  103 respondents).
Total episode cost among respondents differed signifi-
cantly (p  0.02) between H2RAs (median  $84) versus
PPIs (median  $169). 
CONCLUSIONS: This study was not able to detect dif-
ferences in the patient satisfaction and quality of life in
H2RA versus PPI monotherapy in this population. As ex-
pected, episode costs were higher for PPIs versus H2RAs
(primarily due to medication costs).
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OBJECTIVE: To determine the most cost-effective ther-
apy with the payback time for the eradication of Helico-
bacter pylori (Hp) infection in Malaysian duodenal ulcer
(DU) patients during the 1-year assumption period. 
METHODS: Decision analysis was used to compare the to-
tal cost within 1 year for Hp eradication therapies. The five
strategies compared were as follows. 1) Histamine receptor
antagonists (H2RA): acid suppression therapy for 6 weeks
followed by maintenance therapy as needed; 2) BMT 
proton pump inhibitor (PPI): bismuth (120 mg QID), met-
ronidazole (400 mg TID), tetracycline (500 mg QID), and
PPI BID for 7 days; 3) OAC: omeprazole (20 mg BID),
amoxicillin (1000 mg BID), and clarithromycin (500 mg
BID) for 7 days; 4) OMC: omeprazole (20 mg BID), met-
ronidazole (400 mg BID), and clarithromycin (500 mg BID)
for 7 days; 5) OAM: omeprazole (20 mg BID), amoxicillin
(1000 mg BID), and metronidazole (400 mg BID) for 7
days. The Hp eradication, resistance, and compliance rates
for all therapies were used in the decision analysis model.
The assumptions of medication costs, practice patterns, and
the rates used in the model were collected from literature
and from the Malaysian Expert Panel Meeting held in
Kuala Lumpur, June 1997. The total costs over 1 year for
the five treatments were analyzed and averaged by 12
months to determine when the payback period begins for
the most cost-effective triple therapy. 
RESULTS: The 1-year total costs are shown in the table
below.
H2RA maintenance therapy was the most expensive ther-
apy in the beginning and over time. The OAC regimen
was the second most expensive in terms of initial invest-
ment, but this was the most cost-effective therapy over
12 months. OAC begins to save money by month 2, com-
pared to the OMC and BMTPPI therapies. The pay-
back period for OAC, compared to all other therapies be-
gins just 4 months after investment, and from 4 months,
intervention cost savings begins, and continues through-
out the 12-month analysis period. From months 4–12 the
costs of all therapeutic regimens continue to climb—ex-
cept the OAC regimen, which stays at the lowest level, re-
sulting in cost savings. 
CONCLUSION: The payback period for the most cost-
effective regimen, OAC, begins by month 2, and pro-
duces total cost savings by month 4 compared to all other
regimens.
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Therapy H2RA BMT  PPI OMC OAM OAC
Costs (MR) 2335 1839 1786 1775 1679
